Chemists develop ultra-sensitive test cancers, HIV

Chemists develop an ultra-sensitive test for cancers, HIV

9:19 AM, 16th March 2016
Chemists develop an ultra-sensitive test for cancers, HIV
Graduate students Cheng-ting "Jason" Tsai and Peter Robinson prepare a gel electrophoreresis experiment to analyze a DNA-tagged biomarker.

STANFORD, US: A common theme in medicine is that detecting a disease early on can lead to more effective treatments. This relies partly on luck that the patient gets screened at the right time, but more important is that the testing techniques are sensitive enough to register the minuscule hints that diseases leave in the blood stream.

A new technique developed by a team of chemists at Stanford University has shown promise to be thousands of times more sensitive than current techniques in lab experiments, and it is now being put to test in real-world clinical trials.

The research is published in the journal ACS Central Science.

When a disease – whether it’s a cancer or a virus like HIV – begins growing in the body, the immune system responds by producing antibodies. Fishing these antibodies or related biomarkers out of the blood is one way that scientists infer the presence of a disease. This involves designing a molecule that the biomarker will bind to, and which is adorned with an identifying “flag.” Through a series of specialized chemical reactions, known as an immunoassay, researchers can isolate that flag, and the biomarker bound to it, to provide a proxy measurement of the disease.

The new technique, developed in the lab of Carolyn Bertozzi, a professor of chemistry at Stanford, augments this standard procedure with powerful DNA screening technology. In this case, the chemists have replaced the standard flag with a short strand of DNA, which can then be teased out of the sample using DNA isolation technologies that are far more sensitive than those possible for traditional antibody detections.

“This is spiritually related to a basic science tool we were developing to detect protein modifications, but we realized that the core principles were pretty straightforward and that the approach might be better served as a diagnostic tool,” said Peter Robinson, a co-author of the study and graduate student in Bertozzi’s group.

The researchers tested their technique, with its signature DNA flag, against four commercially available, FDA-approved tests for a biomarker for thyroid cancer. It outperformed the sensitivity of all of them, by at least 800 times, and as much as 10,000 times. By detecting the biomarkers of disease at lower concentrations, physicians could theoretically catch diseases far earlier in their progression.

“The thyroid cancer test has historically been a fairly challenging immunoassay, because it produces a lot of false positives and false negatives. We suspected ours would be more sensitive, but we were pleasantly surprised by the magnitude,” Robinson said.

Based on the success of the thyroid screening, the group has won a few grants to advance the technique into clinical trials. One trial underway in collaboration with the nearby Alameda County Public Health Laboratory will help evaluate the technique as a screening tool for HIV. Early detection and treatment of the virus can help ensure that its effects on the patient are minimized and reduce the chance that it is transmitted to others. This effort is supported by a pilot grant from Stanford-Spectrum, funded by the National Center for Advancing Translational Sciences at the National Institutes of Health.

“In contrast to many new diagnostic techniques, this test is performed on pre-existing machines that most clinical labs are already familiar with,” said co-author Cheng-ting “Jason” Tsai, a graduate student in Bertozzi’s group.

The researchers are also pursuing tests for Type 1 diabetes, for which early detection could help patients manage the disease with fewer side effects.

The study was co-authored by Carole Spencer of the University of Southern California. This work was supported in part by a grant from the National Institutes of Health. Bertozzi is also a professor, by courtesy, of radiology and of chemical and systems biology.

© Stanford University News

Related News:

Scientists develop better way to screen chemicals for cancer-causing effects 



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

EU chemicals output shows flat trajectory; trade surplus up by €1.7 bn

BRUSSELS, BELGIUM: European chemical output grew just 0.2 percent during the first ten months of 2015 compared to the same period of 2014, according t ...

Read more
PolyOne appoints new chief commercial officer

CLEVELAND, US: PolyOne Corporation said it has appointed Michael Garratt as senior vice president and chief commercial officer and Donald Wiseman as s ...

Read more
Comet Biorefining to build bio-based chemicals plant in Canada

LONDON, UK: Comet Biorefining Inc said it has received funding to build the first-of-a-kind advanced bio-based chemicals plant in Sarnia (Ontario), Ca ...

Read more
Technip bags Total E&P Angola’s engineering services contract

PARIS, FRANCE: Technip Angola Engenharia Limitada, a joint venture between Technip SA and Sonangol Group said it has been awarded by Total E&P Ang ...

Read more
AkzoNobel’s new UV clear coat technology for fast-track repairs

AMSTERDAM, NETHERLANDS: AkzoNobel NV’s new ultraviolet clear coat technology enables vehicle body shops can now cut their energy costs by up to ...

Read more
SOCAR-KBR JV bags Baku Oil refinery modernization contract

HOUSTON, US: SOCAR-KBR joint venture (JV) said it has been awarded a significant project management consultancy (PMC) contract for the Heydar Aliyev B ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X